


## POLY MEDICURE LIMITED

Regd. Office: 232B, 3rd Floor, Okhla Industrial Estate Phase III, New Delhi - 110 020, Phone: 011-26321889, Fax: 011-26321894  
 Website: polymedicure.com, E-mail: investorcare@polymedicure.com, CIN: L40300DL1995PLC066923  
**UNAUDITED (STANDALONE) FINANCIAL RESULTS FOR THE QUARTER AND YEAR TO DATE ENDED 31ST DECEMBER, 2014**

Part I

| #         | Particulars   | Quarter ended   |                 |                 | Year to date Ended |                  | ₹ in lacs        |
|-----------|---|-----------------|-----------------|-----------------|--------------------|------------------|------------------|
|           |   | 31.12.2014      | 30.09.2014      | 31.12.2013      | 31.12.2014         | 31.12.2013       | 31.03.2014       |
|           |   | (Unaudited)     |                 |                 | (Unaudited)        |                  | (Audited)        |
| <b>1</b>  | <b>Income from operations</b>   |                 |                 |                 |                    |                  |                  |
| a         | Net sales / income from operations<br>(net of excise duty)  | 9,577.10        | 9,386.63        | 7,841.24        | 27,097.09          | 22,402.98        | 30,483.09        |
| b         | Other operating income  | 158.50          | 177.37          | 188.04          | 481.46             | 646.68           | 750.23           |
|           | <b>Total income from operations (net)</b>   | <b>9,735.60</b> | <b>9,564.00</b> | <b>8,029.28</b> | <b>27,578.55</b>   | <b>23,049.66</b> | <b>31,233.32</b> |
| <b>2</b>  | <b>Expenses</b>   |                 |                 |                 |                    |                  |                  |
| a         | Cost of materials consumed  | 3,642.36        | 3,413.60        | 2,597.87        | 9,812.14           | 7,375.93         | 10,085.67        |
| b         | Purchases of stock-in-trade   | 177.63          | 211.84          | 123.98          | 545.11             | 491.92           | 575.91           |
| c         | Changes in inventories of finished goods, work-in-progress<br>and stock-in-trade                    | (269.55)        | (349.04)        | 109.59          | (591.74)           | (109.52)         | (347.48)         |
| d         | Employee benefits expense   | 1,589.85        | 1,588.70        | 1,257.17        | 4,551.06           | 3,650.89         | 4,980.36         |
| e         | Depreciation and amortisation expense   | 478.41          | 447.46          | 339.38          | 1,326.51           | 978.54           | 1,351.06         |
| f         | Other expenses  | 2,381.36        | 2,442.80        | 2,253.88        | 6,930.03           | 6,024.03         | 8,675.50         |
|           | <b>Total expenses</b>   | <b>8,000.06</b> | <b>7,755.36</b> | <b>6,681.87</b> | <b>22,573.11</b>   | <b>18,411.79</b> | <b>25,321.02</b> |
| <b>3</b>  | <b>Profit from operations before other income, finance<br/>costs and exceptional items (1-2)</b>    | <b>1,735.54</b> | <b>1,808.64</b> | <b>1,347.41</b> | <b>5,005.44</b>    | <b>4,637.87</b>  | <b>5,912.30</b>  |
| 4         | Other income  | 397.35          | 186.24          | 4.41            | 698.73             | 45.89            | 106.20           |
| <b>5</b>  | <b>Profit from ordinary activities before finance costs<br/>and exceptional items (3 + 4)</b>       | <b>2,132.89</b> | <b>1,994.88</b> | <b>1,351.82</b> | <b>5,704.17</b>    | <b>4,683.76</b>  | <b>6,018.50</b>  |
| 6         | Finance costs   | 279.95          | 174.20          | 202.84          | 648.52             | 503.78           | 794.87           |
| <b>7</b>  | <b>Profit from ordinary activities after finance costs but<br/>before exceptional items (5 - 6)</b> | <b>1,852.94</b> | <b>1,820.68</b> | <b>1,148.98</b> | <b>5,055.65</b>    | <b>4,179.98</b>  | <b>5,223.63</b>  |
| 8         | Exceptional items   | -               | 1,957.80        | 370.80          | 1,957.80           | 370.80           | 991.46           |
| <b>9</b>  | <b>Profit from ordinary activities before tax (7 + 8)</b>   | <b>1,852.94</b> | <b>3,778.48</b> | <b>1,519.78</b> | <b>7,013.45</b>    | <b>4,550.78</b>  | <b>6,215.09</b>  |
| 10        | Tax expense   | 659.70          | 1,051.21        | 413.80          | 2,122.10           | 1,385.87         | 1,911.88         |
| <b>11</b> | <b>Net Profit from ordinary activities after tax (9 - 10)</b>                                       | <b>1,193.24</b> | <b>2,727.27</b> | <b>1,105.98</b> | <b>4,891.35</b>    | <b>3,164.91</b>  | <b>4,303.21</b>  |
| 12        | Extraordinary items   | -               | -               | -               | -                  | -                | -                |
| <b>13</b> | <b>Net Profit for the period (11 + 12)</b>  | <b>1,193.24</b> | <b>2,727.27</b> | <b>1,105.98</b> | <b>4,891.35</b>    | <b>3,164.91</b>  | <b>4,303.21</b>  |
| 14        | Paid-up equity share capital (Face Value of ₹ 10 each)  | 2,205.67        | 2,204.14        | 2,203.32        | 2,205.67           | 2,203.32         | 2,203.32         |
| 15        | Reserve excluding Revaluation Reserves as per balance<br>sheet of previous accounting year          |                 |                 | -               | -                  |                  | 12,226.21        |
| <b>16</b> | <b>Earnings per share (before extraordinary items)<br/>(not annualised)</b>                         |                 |                 |                 |                    |                  |                  |
|           | Basic ( ₹ )   | 5.38            | 12.38           | 5.01            | 22.18              | 14.36            | 19.53            |
|           | Diluted ( ₹ )   | 5.38            | 12.37           | 5.01            | 22.18              | 14.35            | 19.51            |



*Munawar P.*

**Part II - Select information for the Quarter ended December 31, 2014**

| <b>A PARTICULARS OF SHAREHOLDING</b>   |            |            |            |            |            |            |  |
|--|------------|------------|------------|------------|------------|------------|--|
| <b>1 Public shareholding</b>   |            |            |            |            |            |            |  |
| Number of shares   | 11,331,282 | 11,315,982 | 11,307,773 | 11,331,282 | 11,307,773 | 11,307,773 |  |
| Percentage of shareholding   | 51.37%     | 51.34%     | 51.32%     | 51.37%     | 51.32%     | 51.32%     |  |
| <b>2 Promoters and Promoter Group Shareholding</b>                                     |            |            |            |            |            |            |  |
| <b>a) Pledged / Encumbered</b>   |            |            |            |            |            |            |  |
| Number of shares   | -          | -          | -          | -          | -          | -          |  |
| Percentage of shares (as a % of the total shareholding of promoter and promoter group) | -          | -          | -          | -          | -          | -          |  |
| Percentage of shares (as a % of the total share capital of the company)                | -          | -          | -          | -          | -          | -          |  |
| <b>b) Non - encumbered</b>   |            |            |            |            |            |            |  |
| Number of shares   | 10,725,438 | 10,725,438 | 10,725,438 | 10,725,438 | 10,725,438 | 10,725,438 |  |
| Percentage of shares (as a % of the total shareholding of promoter and promoter group) | 100%       | 100%       | 100%       | 100%       | 100%       | 100%       |  |
| Percentage of shares (as a % of the total share capital of the company)                | 48.63%     | 48.66%     | 48.68%     | 48.63%     | 48.68%     | 48.68%     |  |
| <b>B Investor Complaints</b>   |            |            |            |            |            |            |  |
| Pending at the beginning of the quarter  | Nil        |            |            |            |            |            |  |
| Received during the quarter  | Nil        |            |            |            |            |            |  |
| Disposed of during the quarter   | Nil        |            |            |            |            |            |  |
| Remaining unresolved at the end of the quarter   | Nil        |            |            |            |            |            |  |

**Notes:**

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 4<sup>th</sup> February 2015.
- During the quarter ended December 2014, 15300 equity shares of ₹ 10 each issued under employee stock option scheme were got listed and admitted to dealings on the stock exchanges from 21<sup>st</sup> November 2014.
- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- Effective from 1<sup>st</sup> April 2014, the Company has revised depreciation rate on fixed assets as per the useful life specified in the Companies Act, 2013. Based on current estimates, depreciation of ₹ 60.66 lacs on account of assets whose useful life is already exhausted as on 1<sup>st</sup> April, 2014 and deferred tax of ₹ 20.62 lacs thereon have been adjusted to opening reserves.  
Had there not been any change in useful life of assets, depreciation charged for the quarter and nine months ended 31<sup>st</sup> December 2014 would have been lower by ₹ 10.90 lacs and ₹ 23.97 lacs respectively.
- The equity shares of the company have been sub divided having a face value of ₹ 5 each from ₹ 10 each on record date i.e. 3<sup>rd</sup> February 2015.
- The statutory Auditors have carried out the limited review of the above results.
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

By order of the Board




Himanshu Baid

Managing Director

Place : New Delhi

Date : 04.02.2015



**DOOGAR & ASSOCIATES**  
Chartered Accountants


**Limited Review Report**

The Board of Directors  
Poly Medicare Limited  
232B, 3<sup>rd</sup> Floor, Okhla Industrial Estate  
Phase III  
New Delhi – 110 020

Dear Sirs,

1. We have reviewed the accompanying statement of unaudited financial results of Poly Medicare Limited (the 'Company') for the quarter ended December 31st, 2014 except for the disclosures regarding "Public Shareholding" and "Promoters and Promoters Group Shareholding" which have been traced from disclosures made by the Management and have not been audited by us. These unaudited financial statements are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to issue a report on these unaudited financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards notified under the Companies Act, 1956 (which are deemed to be applicable as per section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014) and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreements with the Stock Exchanges, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates  
Chartered Accountants  
(Reg. No. 000561N)

  
M.S. Agarwal  
(Partner)  
M. No. 86580

Place: New Delhi  
Date: 4<sup>th</sup> February, 2015.